Intelligence Feed event · Equity · 2026-09-19

    Teva Real-World Data Shows UZEDY Superiority in Schizophrenia Continuity

    Question

    Teva Real-World Data Shows UZEDY Superiority in Schizophrenia Continuity

    Direct answer

    Teva Pharmaceutical Industries presented real-world clinical findings showing that UZEDY (extended-release risperidone) delivers superior patient retention relative to alternative long-acting injectable therapies in schizophrenia and oral regimens in bipolar I disorder. The analysis indicated measurable reductions in emergency room visits and hospital readmissions, providing Teva with health-economic evidence to secure preferred commercial insurance formulary status.

    Original publisher
    Market Ontology
    Evidence through
    2026-09-19
    Published
    2026-10-20
    Revision
    1 · 2026-10-20

    Cite as: Market Ontology, “Teva Real-World Data Shows UZEDY Superiority in Schizophrenia Continuity”, revision 1, evidence through 2026-09-19. https://marketontology.com/market-events/2026-09-19/teva-real-world-data-shows-uzedy-superiority-in-schizophrenia-continuity-647244

    EQUITY
    Teva Real-World Data Shows UZEDY Superiority in Schizophrenia Continuity
    Teva Pharmaceutical Industries presented real-world clinical findings showing that UZEDY (extended-release risperidone) delivers superior patient retention relative to alternative long-acting injectable therapies in schizophrenia and oral regimens in bipolar I disorder. The analysis indicated measurable reductions in emergency room visits and hospital readmissions, providing Teva with health-economic evidence to secure preferred commercial insurance formulary status.
    TEVA
    Impact
    66
    SEP 19
    SIG
    89%
    TEVA
    Teva Real-World Data Shows UZEDY Superiority in Schizophrenia Continuity
    Teva Pharmaceutical Industries presented real-world clinical findings showing that UZEDY (extended-release risperidone) delivers superior patient retention relative to alternative long-acting injectable therapies in schizophrenia and oral regimens in bipolar I disorder. The analysis indicated measurable reductions in emergency room visits and hospital readmissions, providing Teva with health-economic evidence to secure preferred commercial insurance formulary status.
    → Demonstrated reduction in hospitalizations and emergency room visits supports formulary tier placement and commercial volume adoption for TEVA.
    Impact
    Teva Pharmaceutical Industries presented real-world clinical findings showing that UZEDY (extended-release risperidone) delivers superior patient retention relative to alternative long-acting injectable therapies in schizophrenia and oral regimens in bipolar I disorder. The analysis indicated measurable reductions in emergency room visits and hospital readmissions, providing Teva with health-economic evidence to secure preferred commercial insurance formulary status.
    Affected
    TEVA
    Transmission
    Demonstrated reduction in hospitalizations and emergency room visits supports formulary tier placement and commercial volume adoption for TEVA.

    How this development reaches the affected companies

    AssetExposure and channelDirectionEvidence
    TEVAcommercial formulary access expansion and specialty pharma revenue growthUp1-3mReal-world study confirms treatment continuity and healthcare cost reduction for UZEDY.

    Does this development affect your holdings?

    Enter your holdings to check them against this and other recent developments, review the decision that matters most, then set a monitor.

    Check this development against my holdings

    Review your initial audit before choosing ongoing portfolio scanning at $79/month.

    What happened next

    Price follow-up pending — no stored daily closes for these assets yet.

    Closing prices from stored daily bars; returns measured from the last close on or before the event date. Not a recommendation.

    No verifiable public source recorded for this card.

    Related

    Check this development against my holdings

    See today's live cards

    Public pages are published 24 hours after the product shows them. Desk shows every catalyst, event and causal reading as it happens, mapped to your holdings.

    Open Desk — $399/month